STERIS plc (STE) reported better-than-expected financial results for the second quarter of fiscal 2026. The company achieved earnings per share (EPS) of $2.47, surpassing Wall Street's consensus estimate of $2.37 by $0.10. Additionally, revenue reached $1.5 billion, exceeding the anticipated $1.4 billion.
This update provides insight into STERIS's operational performance and financial health, reflecting stronger-than-anticipated business fundamentals. The company operates within the health care industry, focusing on providing healthcare and life science products and services. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences, which collectively support a wide range of healthcare providers and manufacturers.
STERIS will host its earnings conference call after market close to discuss these results and provide additional commentary on business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a comprehensive understanding of the quarter's performance.
As of November 8, 2025, STERIS has a market capitalization of $25.85 billion and a trailing P/E ratio of 42.06. The company’s upcoming earnings report is scheduled for August 3, 2026, with EPS estimates of $2.5408 and revenue expectations of $1.5 billion.